

2<sup>nd</sup> meeting of WG Nutrition Support in Sydney (31/10/2011)

The agenda of the proceedings

Participants (following the visitors' list)

Dr. Ritsuro Suzuki (University of Nagoya, Japan)

Dr. Sung-Won Kim (National Cancer Center Hospital, Japan)

Dr. Shigeo Fuji (University of Wuerzburg, Germany)

Dr. Keisuke Watanabe (Anjo Kosei Hospital, Japan)

Dr. Shiro Koh (Osaka City University, Japan)

Dr. Kimikazu Yakushijin (Kobe University, Japan)

Dr. Young Rok Do (Dongsan Medical Center Keimyung University, Korea)

Dt. Yui Hung (University of Queensland, Australia)

Dt. Jessica Cheng (St Vincent's hospital, Australia)

Dt. Annabel Horne (St Vincent's hospital, Australia)

Dr. Takeshi Mori (Keio University hospital, Japan)

Dr. Sumiko Kohashi (Keio University hospital, Japan)

Chairman (Dr. Kim, Dr. Fuji)

1. Introduction (Dr. Fuji, University Hospital of Wuerzburg, Germany)

Dr. Fuji gave an opening address.

2. Ongoing studies in Japan (Dr. Kim, National Cancer Center Hospital, Japan)

Dr. Kim reported the current status of ongoing studies relating nutritional support in HSCT in Japan.

He told us that the first study (NST-01) will finish soon, and the other studies still need more time to enroll the patients.

He introduced GFO and oligopeptide (Peptino).

Dr. Mori asked how patients tolerated the supplemental foods, and he is interested in NST-02 and NST-04.

Dr. Kim will send him the protocol and the relating documents.

3. EN after allogeneic HSCT (Dt. Cheng, St Vincent's hospital)

Dt. Cheng reviewed the previous literatures and reported her experiences.

In Australia, the prospective study of EN is planned.

Possibly, we as WG can take part in that study somehow.

4. Proposal of clinical trial (Dr. Fuji, University Hospital of Wuerzburg)

Dr. Fuji proposed the clinical trial assessing the prevalence of malnutrition and its impact on the clinical outcome after allogeneic hematopoietic stem cell transplantation.

Dr. Fuji will send the draft by mailing list soon.

After we receive the opinions from our colleagues and discuss about them, we will submit the protocol to the office of APBMT. After the approval by APBMT, we will submit the protocol to IRB in NCCH, Japan. I expect that it will take several months.

5. Proposal of the clinical trial (Dr. Kim, National Cancer Center Hospital)

Dr. Kim proposed the clinical trial assessing the effect of intensive glucose control (target 80-110 mg/dL) to the conventional glucose control (80-180 mg/dL) after allogeneic HSCT. At first, we have to wait for the results of NST-01 and check whether the current protocol of glucose control used in NST-01 has any problems or not. After that, Dr. Fuji will send the draft by mailing list, and discuss about it.

6. Closing remarks (Dr. Kim, National Cancer Center Hospital)

Shigeo Fuji